JP2017513818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513818A5 JP2017513818A5 JP2016557287A JP2016557287A JP2017513818A5 JP 2017513818 A5 JP2017513818 A5 JP 2017513818A5 JP 2016557287 A JP2016557287 A JP 2016557287A JP 2016557287 A JP2016557287 A JP 2016557287A JP 2017513818 A5 JP2017513818 A5 JP 2017513818A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- antigen
- cancer
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 CS-1 Proteins 0.000 claims 57
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 53
- 239000000427 antigen Substances 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 34
- 230000011664 signaling Effects 0.000 claims 28
- 206010028980 Neoplasm Diseases 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 239000012642 immune effector Substances 0.000 claims 20
- 229940121354 immunomodulator Drugs 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 102100024263 CD160 antigen Human genes 0.000 claims 15
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 15
- 230000000139 costimulatory effect Effects 0.000 claims 15
- 230000004068 intracellular signaling Effects 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 239000013598 vector Substances 0.000 claims 15
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 14
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 13
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 13
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 12
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 12
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 12
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 12
- 102100029197 SLAM family member 6 Human genes 0.000 claims 12
- 102100038083 Endosialin Human genes 0.000 claims 11
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 10
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 10
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 10
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 10
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 10
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 10
- 102100025390 Integrin beta-2 Human genes 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 102100038078 CD276 antigen Human genes 0.000 claims 8
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 8
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 8
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 8
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 8
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 8
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 8
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 8
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 8
- 102100039904 Integrin alpha-D Human genes 0.000 claims 8
- 102100022297 Integrin alpha-X Human genes 0.000 claims 8
- 102100025304 Integrin beta-1 Human genes 0.000 claims 8
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 8
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 8
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 8
- 102100029198 SLAM family member 7 Human genes 0.000 claims 8
- 102100027744 Semaphorin-4D Human genes 0.000 claims 8
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 8
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 7
- 108060006698 EGF receptor Proteins 0.000 claims 7
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 7
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims 7
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 7
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims 7
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 claims 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 6
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims 6
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 claims 6
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 6
- 108700012439 CA9 Proteins 0.000 claims 6
- 102100027207 CD27 antigen Human genes 0.000 claims 6
- 102100029390 CMRF35-like molecule 1 Human genes 0.000 claims 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 6
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 claims 6
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 claims 6
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 6
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims 6
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 6
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 6
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 6
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 6
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 6
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 6
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 6
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims 6
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims 6
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 claims 6
- 101710107067 Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 claims 6
- 102100022341 Integrin alpha-E Human genes 0.000 claims 6
- 102100022338 Integrin alpha-M Human genes 0.000 claims 6
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 claims 6
- 101710196509 Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 claims 6
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 claims 6
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 claims 6
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 claims 6
- 101710187841 Olfactory receptor 51E2 Proteins 0.000 claims 6
- 102100032364 Pannexin-3 Human genes 0.000 claims 6
- 101710165197 Pannexin-3 Proteins 0.000 claims 6
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims 6
- 108050005093 Placenta-specific protein 1 Proteins 0.000 claims 6
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 claims 6
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims 6
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 6
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 6
- 101710149284 Protein SSX2 Proteins 0.000 claims 6
- 102100037686 Protein SSX2 Human genes 0.000 claims 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 6
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 claims 6
- 206010039491 Sarcoma Diseases 0.000 claims 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 6
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 6
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 6
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims 6
- 102000013532 Uroplakin II Human genes 0.000 claims 6
- 108010065940 Uroplakin II Proteins 0.000 claims 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 6
- 102100039490 X antigen family member 1 Human genes 0.000 claims 6
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 6
- 108010073531 rhoC GTP-Binding Protein Proteins 0.000 claims 6
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 claims 6
- 230000005945 translocation Effects 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 5
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 5
- 102100032187 Androgen receptor Human genes 0.000 claims 5
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims 5
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 108010058905 CD44v6 antigen Proteins 0.000 claims 5
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 claims 5
- 102100038449 Claudin-6 Human genes 0.000 claims 5
- 108010060385 Cyclin B1 Proteins 0.000 claims 5
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 5
- 102000010449 Folate receptor beta Human genes 0.000 claims 5
- 108050001930 Folate receptor beta Proteins 0.000 claims 5
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims 5
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims 5
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 5
- 102000010956 Glypican Human genes 0.000 claims 5
- 108050001154 Glypican Proteins 0.000 claims 5
- 108050007237 Glypican-3 Proteins 0.000 claims 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 claims 5
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 5
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims 5
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 5
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 claims 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 5
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 5
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 5
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims 5
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 5
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 5
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 claims 5
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 5
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 5
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims 5
- 102100034256 Mucin-1 Human genes 0.000 claims 5
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 claims 5
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 claims 5
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 5
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 5
- 102100022748 Wilms tumor protein Human genes 0.000 claims 5
- 101710127857 Wilms tumor protein Proteins 0.000 claims 5
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 108010080146 androgen receptors Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 5
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108010056102 CD100 antigen Proteins 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 4
- 108010062802 CD66 antigens Proteins 0.000 claims 4
- 102100027217 CD82 antigen Human genes 0.000 claims 4
- 101710139831 CD82 antigen Proteins 0.000 claims 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 4
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims 4
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 4
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims 4
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims 4
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 4
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 4
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 4
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 4
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 4
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 4
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 4
- 102100022339 Integrin alpha-L Human genes 0.000 claims 4
- 108010041100 Integrin alpha6 Proteins 0.000 claims 4
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 4
- 102100033016 Integrin beta-7 Human genes 0.000 claims 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 4
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims 4
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 4
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 4
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 4
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100029216 SLAM family member 5 Human genes 0.000 claims 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 4
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 102000017578 LAG3 Human genes 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 108010017009 CD11b Antigen Proteins 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 102100037904 CD9 antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101100534087 Cowpox virus (strain Brighton Red) CRMA gene Proteins 0.000 claims 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 2
- 208000017815 Dendritic cell tumor Diseases 0.000 claims 2
- 102000011107 Diacylglycerol Kinase Human genes 0.000 claims 2
- 108010062677 Diacylglycerol Kinase Proteins 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 2
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims 2
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims 2
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108091007065 BIRCs Proteins 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108090000229 Claudin-6 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000012804 EPCAM Human genes 0.000 claims 1
- 101150084967 EPCAM gene Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 101710144543 Endosialin Proteins 0.000 claims 1
- 102100023721 Ephrin-B2 Human genes 0.000 claims 1
- 108010044090 Ephrin-B2 Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 102000010451 Folate receptor alpha Human genes 0.000 claims 1
- 108050001931 Folate receptor alpha Proteins 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000027583 GPCRs class C Human genes 0.000 claims 1
- 108091008882 GPCRs class C Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 102000044445 Galectin-8 Human genes 0.000 claims 1
- 102100039554 Galectin-8 Human genes 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 claims 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 101150102264 IE gene Proteins 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 1
- 102100034872 Kallikrein-4 Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102000016200 MART-1 Antigen Human genes 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 101710151472 Neuroendocrine convertase 1 Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims 1
- 101710149060 Paired box protein Pax-3 Proteins 0.000 claims 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 claims 1
- 108091081548 Palindromic sequence Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 claims 1
- 108050009432 Plexin domain-containing protein 1 Proteins 0.000 claims 1
- 108091036407 Polyadenylation Proteins 0.000 claims 1
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 208000007541 Preleukemia Diseases 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100026034 Protein BTG2 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 101800001271 Surface protein Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 101150057140 TACSTD1 gene Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 1
- 108010056354 Ubiquitin C Proteins 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 101710101493 Viral myc transforming protein Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003259 immunoinhibitory effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 108010024383 kallikrein 4 Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 101710135378 pH 6 antigen Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 108010013873 proacrosin Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953783P | 2014-03-15 | 2014-03-15 | |
| US61/953,783 | 2014-03-15 | ||
| US201461976375P | 2014-04-07 | 2014-04-07 | |
| US61/976,375 | 2014-04-07 | ||
| US201462027154P | 2014-07-21 | 2014-07-21 | |
| US62/027,154 | 2014-07-21 | ||
| US201462076146P | 2014-11-06 | 2014-11-06 | |
| US62/076,146 | 2014-11-06 | ||
| US201462097286P | 2014-12-29 | 2014-12-29 | |
| US62/097,286 | 2014-12-29 | ||
| PCT/US2015/020606 WO2015142675A2 (en) | 2014-03-15 | 2015-03-13 | Treatment of cancer using chimeric antigen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126002A Division JP6860623B2 (ja) | 2014-03-15 | 2019-07-05 | キメラ抗原受容体を使用する癌の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513818A JP2017513818A (ja) | 2017-06-01 |
| JP2017513818A5 true JP2017513818A5 (enExample) | 2018-04-19 |
Family
ID=52780057
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557287A Pending JP2017513818A (ja) | 2014-03-15 | 2015-03-13 | キメラ抗原受容体を使用する癌の処置 |
| JP2019126002A Active JP6860623B2 (ja) | 2014-03-15 | 2019-07-05 | キメラ抗原受容体を使用する癌の処置 |
| JP2021053240A Active JP7526121B2 (ja) | 2014-03-15 | 2021-03-26 | キメラ抗原受容体を使用する癌の処置 |
| JP2024115421A Pending JP2024164002A (ja) | 2014-03-15 | 2024-07-19 | キメラ抗原受容体を使用する癌の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126002A Active JP6860623B2 (ja) | 2014-03-15 | 2019-07-05 | キメラ抗原受容体を使用する癌の処置 |
| JP2021053240A Active JP7526121B2 (ja) | 2014-03-15 | 2021-03-26 | キメラ抗原受容体を使用する癌の処置 |
| JP2024115421A Pending JP2024164002A (ja) | 2014-03-15 | 2024-07-19 | キメラ抗原受容体を使用する癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20170335281A1 (enExample) |
| EP (2) | EP3119423B1 (enExample) |
| JP (4) | JP2017513818A (enExample) |
| CN (1) | CN106163547A (enExample) |
| ES (1) | ES2939760T3 (enExample) |
| WO (1) | WO2015142675A2 (enExample) |
Families Citing this family (501)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9724404B2 (en) | 2009-04-13 | 2017-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | HPV particles and uses thereof |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| KR102685501B1 (ko) | 2013-02-20 | 2024-07-17 | 노파르티스 아게 | 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료 |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN112795594B (zh) | 2013-05-14 | 2025-09-19 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
| WO2015042325A1 (en) | 2013-09-18 | 2015-03-26 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
| CA3225456A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| JP6640726B2 (ja) | 2014-02-14 | 2020-02-05 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体及びその製造方法 |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| CN111514283B (zh) | 2014-04-07 | 2025-10-14 | 诺华股份有限公司 | 使用抗cd19嵌合抗原受体治疗癌症 |
| KR102508166B1 (ko) | 2014-04-10 | 2023-03-13 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 세포 면역요법을 위한 방법 및 조성물 |
| CN106535925A (zh) | 2014-05-23 | 2017-03-22 | 佛罗里达大学研究基金会有限公司 | 基于car的免疫治疗 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| EP3172234B1 (en) | 2014-07-21 | 2020-04-08 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| WO2016014530A1 (en) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| EP3182994B1 (en) * | 2014-08-19 | 2019-12-04 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor specific for ssea4 antigen |
| AU2015305531B2 (en) | 2014-08-19 | 2021-05-20 | Novartis Ag | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment |
| ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
| US10774388B2 (en) | 2014-10-08 | 2020-09-15 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
| ES2987087T3 (es) | 2014-12-03 | 2024-11-13 | Juno Therapeutics Inc | Métodos y composiciones para terapia celular adoptiva |
| CN109072199B (zh) * | 2014-12-05 | 2022-10-28 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的嵌合抗原受体及其用途 |
| JP6997620B2 (ja) | 2014-12-05 | 2022-02-04 | メモリアル スローン ケタリング キャンサー センター | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
| EP3227324A4 (en) | 2014-12-05 | 2018-08-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| LT3227339T (lt) | 2014-12-05 | 2022-01-10 | Memorial Sloan-Kettering Cancer Center | Chimeriniai antigeno receptoriai, nukreipti į receptorių su prijungtu g baltymu ir jų naudojimo būdai |
| RS61781B1 (sr) | 2014-12-05 | 2021-06-30 | Memorial Sloan Kettering Cancer Center | Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe |
| WO2016098078A2 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
| CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3256492A4 (en) | 2015-02-09 | 2018-07-11 | University of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
| US11248058B2 (en) | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| KR102133857B1 (ko) | 2015-03-02 | 2020-07-20 | 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 | Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소 |
| WO2016149254A1 (en) | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016164370A1 (en) | 2015-04-06 | 2016-10-13 | Ohio State Innovation Foundation | Egfr-directed car therapy for glioblastoma |
| CA2981751A1 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3317401B1 (en) * | 2015-07-29 | 2018-10-03 | Onkimmune Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CA2993431A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Nuclease based knockouts of immunological checkpoint genes in immune cells |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| GB201514874D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
| CN108135932A (zh) * | 2015-08-28 | 2018-06-08 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| WO2017053889A2 (en) | 2015-09-23 | 2017-03-30 | Precision Immunotherapy, Inc. | Flt3 directed car cells for immunotherapy |
| CN105567649A (zh) * | 2015-10-26 | 2016-05-11 | 哈尔滨新联合生物科技有限公司 | 一种修饰的增强型dc-cik靶向免疫细胞群的制备方法和用途 |
| WO2017075147A1 (en) * | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| JP2018536434A (ja) | 2015-10-30 | 2018-12-13 | アレタ・バイオセラピューティクス・インコーポレイテッドＡｌｅｔａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 腫瘍形質導入のための組成物及び方法 |
| US11207339B2 (en) | 2015-10-30 | 2021-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Targeted cancer therapy |
| CA3004748C (en) * | 2015-11-18 | 2021-11-16 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| JP2019500028A (ja) | 2015-11-19 | 2019-01-10 | ブラッドセンター リサーチ ファウンデーション | 癌免疫療法で使用するための二重特異性ｔ細胞を製造する方法 |
| EP4212547A1 (en) * | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| IL259747B (en) | 2015-12-04 | 2022-09-01 | Memorial Sloan Kettering Cancer Center | Antibodies against fcrl5 and methods of their use |
| NZ782858A (en) | 2015-12-04 | 2025-08-29 | Novartis Ag | Compositions and methods for immunooncology |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| EP4643874A2 (en) | 2015-12-22 | 2025-11-05 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| EP3397755B1 (en) | 2015-12-28 | 2024-11-06 | Novartis AG | Methods of making chimeric antigen receptor -expressing cells |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| KR20180101554A (ko) | 2016-01-20 | 2018-09-12 | 더 스크립스 리서치 인스티튜트 | Ｒｏｒ１ 항체 조성물 및 관련 방법 |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| WO2017144681A1 (en) * | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Binding members to pd-l1 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| US11767362B1 (en) * | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3436482A4 (en) | 2016-03-29 | 2020-03-11 | OBI Pharma, Inc. | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| KR102584300B1 (ko) | 2016-03-29 | 2023-10-05 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR102397674B1 (ko) | 2016-04-01 | 2022-05-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| UA128781C2 (uk) | 2016-04-01 | 2024-10-23 | Кайт Фарма, Інк. | Т-клітина, спосіб її отримання та застосування |
| WO2017173410A1 (en) * | 2016-04-01 | 2017-10-05 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| CN113082201B (zh) | 2016-04-01 | 2024-07-05 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
| JP2019510503A (ja) * | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| JP6987390B2 (ja) * | 2016-04-08 | 2021-12-22 | エモリー ユニバーシティー | 細胞ベースの治療法を用いて癌および感染性疾患を処置する方法 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017178562A1 (en) * | 2016-04-12 | 2017-10-19 | Philogen S.P.A. | Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell |
| CN106399255B (zh) * | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
| CN105907719B (zh) * | 2016-04-18 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Anti ROBO1 CAR-T细胞及其制备和应用 |
| JP7544465B2 (ja) | 2016-04-22 | 2024-09-03 | オービーアイ ファーマ，インコーポレイテッド | グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法 |
| WO2017190096A1 (en) * | 2016-04-29 | 2017-11-02 | University Of Florida Research Foundation Incorporated | Chimeric antigen receptors and uses thereof |
| GB201607968D0 (en) * | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| US11299546B2 (en) | 2016-05-27 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| WO2017214333A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| WO2018012895A1 (ko) * | 2016-07-14 | 2018-01-18 | 주식회사 큐로셀 | 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물 |
| WO2018013862A1 (en) | 2016-07-14 | 2018-01-18 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
| CA3030837A1 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| CN106220736B (zh) * | 2016-07-20 | 2020-01-10 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体、表达其的细胞及其制备方法和用途 |
| AU2017301826A1 (en) * | 2016-07-26 | 2019-03-14 | Tessa Therapeutics Ltd. | Chimeric antigen receptor |
| KR20190067765A (ko) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| KR20230100748A (ko) | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3032838A1 (en) * | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| CA3000514A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
| RU2767206C2 (ru) * | 2016-08-12 | 2022-03-16 | Тулджен Инкорпорейтед | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента |
| WO2018035413A1 (en) * | 2016-08-18 | 2018-02-22 | The Uab Research Foundation | Compositions and methods for cancer immunotherapy |
| CN109789164B (zh) * | 2016-08-30 | 2023-04-28 | 亘喜生物科技（上海）有限公司 | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |
| JP7045378B2 (ja) | 2016-09-01 | 2022-03-31 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ最適化ＣＡＲ Ｔ細胞 |
| CN107793482A (zh) * | 2016-09-06 | 2018-03-13 | 广州百尼夫生物科技有限公司 | 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用 |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| AU2017322414A1 (en) * | 2016-09-08 | 2019-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of treating cancer |
| CN106434563B (zh) * | 2016-09-14 | 2017-09-22 | 深圳市默赛尔生物医学科技发展有限公司 | 转基因自然杀伤细胞及其制备方法和应用 |
| CA3039406A1 (en) | 2016-09-19 | 2018-03-22 | University Of Southern California | Non-radioactive cytotoxicity assays |
| US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| CN107868791B (zh) * | 2016-09-26 | 2021-11-23 | 阿思科力(苏州)生物科技有限公司 | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 |
| JP2019532672A (ja) | 2016-09-28 | 2019-11-14 | ノバルティス アーゲー | 多孔質膜系巨大分子送達システム |
| CN106317228A (zh) * | 2016-09-28 | 2017-01-11 | 李华顺 | 一种嵌合抗原受体分子及其应用 |
| AU2017336094A1 (en) * | 2016-09-29 | 2019-04-18 | Immunitybio, Inc. | HLA class I-deficient NK-92 cells with decreased immunogenicity |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| KR20250011252A (ko) * | 2016-09-30 | 2025-01-21 | 포세이다 테라퓨틱스, 인크. | 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법 |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110225927B (zh) | 2016-10-07 | 2024-01-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
| AU2017342176A1 (en) * | 2016-10-10 | 2019-05-02 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| MX2019003683A (es) | 2016-10-11 | 2019-08-22 | Agenus Inc | Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos. |
| MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| WO2018075794A1 (en) | 2016-10-19 | 2018-04-26 | City Of Hope | Use of triplex cmv vaccine in car t cell therapy |
| CN107988164B (zh) * | 2016-10-26 | 2020-07-07 | 阿思科力(苏州)生物科技有限公司 | 一种pd-1 car nk-92细胞及其制备方法与应用 |
| CN106591363A (zh) * | 2016-11-11 | 2017-04-26 | 广东万海细胞生物科技有限公司 | 一种通用型异体car‑t细胞制备方法及应用 |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| WO2018102786A1 (en) * | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| AU2017368331A1 (en) * | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| CN106701827A (zh) * | 2016-12-05 | 2017-05-24 | 刘晓明 | 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法 |
| WO2018106729A1 (en) * | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| ES2926397T3 (es) | 2016-12-09 | 2022-10-26 | Onk Therapeutics Ltd | Células asesinas naturales manipuladas y usos de las mismas |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| US20210187022A1 (en) * | 2016-12-21 | 2021-06-24 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| US20190352363A1 (en) | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018115458A1 (en) * | 2016-12-23 | 2018-06-28 | Virttu Biologics Limited | Treatment of cancer |
| US20190336533A1 (en) | 2016-12-28 | 2019-11-07 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| CN107286246B (zh) * | 2016-12-28 | 2019-12-17 | 时力生物科技（北京）有限公司 | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| EP3568416A4 (en) * | 2017-01-13 | 2020-07-08 | Celdara Medical, LLC | TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS |
| TWI780104B (zh) | 2017-01-17 | 2022-10-11 | 日商第一三共股份有限公司 | 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途 |
| EP3570850A4 (en) * | 2017-01-18 | 2020-10-14 | Thalia Papayannopoulou | PACKAGING COMPOSITIONS AND METHODS FOR A TRANSPLANT RECEIVER |
| CN108330133B (zh) * | 2017-01-20 | 2020-06-30 | 上海恒润达生生物科技有限公司 | 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途 |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3577134A1 (en) * | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| AU2018218753A1 (en) * | 2017-02-07 | 2019-09-26 | Daiichi Sankyo Company, Limited | Anti-GPRC5D antibody and molecule containing same |
| KR20190116420A (ko) | 2017-02-17 | 2019-10-14 | 프레드 헛친슨 켄서 리서치 센터 | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| KR102664453B1 (ko) * | 2017-02-21 | 2024-05-10 | 주식회사 유틸렉스 | Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법 |
| TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
| AU2018235756B2 (en) * | 2017-03-13 | 2024-08-08 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| JP7061134B2 (ja) * | 2017-03-20 | 2022-04-27 | ユニバーシティ オブ サザン カリフォルニア | 薬剤負荷ナノ粒子が表面に結合したｃａｒ ｔ細胞の養子移入およびその使用 |
| JP2020513832A (ja) | 2017-03-22 | 2020-05-21 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| CN107271675B (zh) * | 2017-03-24 | 2020-06-02 | 郑猛 | 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用 |
| UA128717C2 (uk) | 2017-03-27 | 2024-10-09 | Ф. Хоффманн-Ля Рош Аг | Поліпшені антигензв'язуючі рецептори |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| SG10201913582XA (en) * | 2017-04-26 | 2020-02-27 | Eureka Therapeutics Inc | Constructs specifically recognizing glypican 3 and uses thereof |
| KR20180123445A (ko) | 2017-05-08 | 2018-11-16 | 주식회사 툴젠 | 인위적으로 조작된 조작면역세포 |
| CN109790518A (zh) * | 2017-05-08 | 2019-05-21 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP7381345B2 (ja) | 2017-05-16 | 2023-11-15 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｍａｎａボディおよび使用方法 |
| CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| EP3630846A4 (en) * | 2017-05-31 | 2021-02-24 | Carsgen Therapeutics Co., Ltd. | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY |
| US11566223B2 (en) * | 2017-06-01 | 2023-01-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cell preparation and uses thereof |
| CN119899277A (zh) | 2017-06-02 | 2025-04-29 | 辉瑞公司 | 靶向flt3的嵌合抗原受体 |
| CN108977453A (zh) | 2017-06-02 | 2018-12-11 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用 |
| CN110799640B (zh) * | 2017-06-07 | 2024-11-12 | 综合医院公司 | 表达嵌合抗原受体的t细胞 |
| CN110944652A (zh) * | 2017-06-12 | 2020-03-31 | 爱莫里大学 | T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途 |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| CN109134660B (zh) * | 2017-06-16 | 2022-07-01 | 上海恒润达生生物科技股份有限公司 | 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途 |
| AU2018288863A1 (en) * | 2017-06-22 | 2020-01-30 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
| CN107164412B (zh) * | 2017-06-30 | 2020-10-23 | 山东兴瑞生物科技有限公司 | 一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用 |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| AU2018292181B2 (en) | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| CN109232742B (zh) * | 2017-07-11 | 2021-10-22 | 深圳市第二人民医院 | 一种嵌合抗原受体及其应用 |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
| CN107326014B (zh) * | 2017-07-31 | 2019-09-24 | 时力生物科技（北京）有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| CN111511762B (zh) * | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| BR112020003646A2 (pt) | 2017-08-31 | 2020-09-01 | Daiichi Sankyo Company, Limited | cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal. |
| KR102630307B1 (ko) | 2017-08-31 | 2024-01-29 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| US12350312B2 (en) | 2017-09-06 | 2025-07-08 | Fred Hutchinson Cancer Center | Methods for improving adoptive cell therapy |
| KR20250006980A (ko) * | 2017-09-15 | 2025-01-13 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| WO2019067677A1 (en) | 2017-09-29 | 2019-04-04 | Cell Design Labs, Inc. | METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR |
| CN107557341B (zh) * | 2017-09-30 | 2020-06-30 | 山东兴瑞生物科技有限公司 | 一种抗wt1增强型嵌合抗原受体修饰的免疫细胞及其应用 |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| US12467050B2 (en) * | 2017-10-02 | 2025-11-11 | Georgia Tech Research Corporation | Methods and compositions for engineering synthetic bioswitches for remote control of biological activity |
| US20200308279A1 (en) * | 2017-10-06 | 2020-10-01 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| AU2018349093A1 (en) * | 2017-10-12 | 2020-05-28 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| TWI829655B (zh) | 2017-10-18 | 2024-01-21 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
| EP3697435A1 (en) * | 2017-10-20 | 2020-08-26 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| CN111566124A (zh) | 2017-10-25 | 2020-08-21 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| TW201932482A (zh) | 2017-11-01 | 2019-08-16 | 美商奇諾治療有限公司 | 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸 |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
| AU2018363292A1 (en) | 2017-11-13 | 2020-05-21 | Crescendo Biologics Limited | Molecules that bind to CD137 and PSMA |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| AU2018370195B2 (en) | 2017-11-14 | 2022-01-13 | Green Cross Lab Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| EP3710471A1 (en) | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| CN107916269B (zh) * | 2017-11-17 | 2020-12-11 | 山东兴瑞生物科技有限公司 | 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用 |
| JP7542438B2 (ja) * | 2017-11-21 | 2024-08-30 | ノバルティス アーゲー | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
| EP3720882A4 (en) * | 2017-12-05 | 2021-10-27 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | T LYMPHOCYTES INCLUDING TWO DIFFERENT ANTIGENIC CHEMERICAL RECEPTORS AND THEIR USES |
| JP7437705B2 (ja) | 2017-12-05 | 2024-02-26 | ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター | 抗ｃｄ３８及び抗ｃｄ１３８キメラ抗原受容体を含むｔ細胞、及びその用途 |
| AU2018385694B2 (en) * | 2017-12-14 | 2022-01-20 | 2Seventy Bio, Inc. | NKG2D DARIC receptors |
| CN118878697A (zh) | 2017-12-20 | 2024-11-01 | 波赛达治疗公司 | Vcar组合物和使用方法 |
| ES3037765T3 (en) | 2017-12-22 | 2025-10-07 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| CA3086669A1 (en) * | 2017-12-28 | 2019-07-04 | NEUGATE PHARMA, LLC aka NEUGATE THERANOSTICS | Compositions and formulations for treatment of malignancies |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| EP3731849A4 (en) | 2017-12-28 | 2021-12-01 | Codiak BioSciences, Inc. | EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY |
| CN109971722B (zh) * | 2017-12-28 | 2023-09-01 | 上海细胞治疗研究院 | 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途 |
| CN108103105A (zh) * | 2017-12-29 | 2018-06-01 | 深圳市茵冠生物科技有限公司 | 一种car-t细胞的制备方法、制得的car-t细胞及其应用 |
| US12491153B2 (en) | 2018-01-03 | 2025-12-09 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| EP3508855A1 (en) * | 2018-01-05 | 2019-07-10 | Allianz Pharmascience Ltd | Method for the selection of patients and kit |
| TW201930591A (zh) * | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| EP3737400A4 (en) | 2018-01-09 | 2021-10-27 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | COMPOSITIONS AND METHODS FOR TARGETING CLEC12A-EXPRESSING CANCERS |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| ES2908324T5 (en) * | 2018-01-12 | 2025-06-05 | Curocell Inc | Enhanced immune cells using dual shrna and composition including the same |
| TWI753229B (zh) * | 2018-01-17 | 2022-01-21 | 美商明塞特製藥公司 | 用於治療癌症之組合療法 |
| WO2019141774A1 (en) | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CN110093351B (zh) * | 2018-01-29 | 2023-06-23 | 华南生物医药研究院 | 可分离的核酸、多肽、重组载体、重组细胞及应用 |
| US20210038659A1 (en) * | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2019160815A1 (en) | 2018-02-13 | 2019-08-22 | Chimera Bioengineering, Inc. | Coordinating gene expression using rna destabilizing elements |
| WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| TW202000229A (zh) * | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| EP3762410A4 (en) | 2018-03-06 | 2022-04-06 | The Trustees of the University of Pennsylvania | CHEMICAL PROSTATE MEMBRANE SPECIFIC ANTIGEN SPECIFIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF |
| KR20210013013A (ko) * | 2018-03-09 | 2021-02-03 | 카르스젠 테라퓨틱스 리미티드 | 종양 치료 방법 및 조성물 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
| WO2019178420A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US12280119B2 (en) | 2018-03-23 | 2025-04-22 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| US10688182B2 (en) * | 2018-03-29 | 2020-06-23 | Cho Pharma Usa, Inc. | Monoclonal antibodies that bind to SSEA4 and uses thereof |
| WO2019192972A1 (en) * | 2018-04-04 | 2019-10-10 | F. Hoffmann-La Roche Ag | Diagnostic assays to detect tumor antigens in cancer patients |
| US20190328781A1 (en) * | 2018-04-06 | 2019-10-31 | Mustang Bio, Inc. | Manufacturing methods for cell-based therapeutic compositions |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019209557A1 (en) | 2018-04-27 | 2019-10-31 | Mayo Foundation For Medical Education And Research | Foamy viruses and methods of use |
| CA3097885A1 (en) * | 2018-04-27 | 2019-10-31 | Crispr Therapeutics Ag | Methods and compositions of cytotoxic t cell depletion |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| CN110438082B (zh) * | 2018-05-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | 表达il-21r结合蛋白的免疫效应细胞 |
| IL278348B2 (en) | 2018-05-11 | 2025-03-01 | Crispr Therapeutics Ag | Methods and preparations for treating cancer |
| US11963981B2 (en) | 2018-05-15 | 2024-04-23 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| KR20220080044A (ko) * | 2018-05-16 | 2022-06-14 | 얀센 바이오테크 인코포레이티드 | 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체 |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| CN108623683B (zh) * | 2018-05-30 | 2021-06-04 | 福州迈新生物技术开发有限公司 | 抗Pax-5蛋白的单克隆抗体及其细胞株、制备方法和应用 |
| CN108715859B (zh) * | 2018-05-31 | 2021-08-03 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd22的嵌合抗原受体及其应用 |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| CA3101517A1 (en) * | 2018-06-01 | 2019-12-05 | Obi Pharma, Inc. | Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody |
| CN110577604A (zh) * | 2018-06-07 | 2019-12-17 | 亘喜生物科技（上海）有限公司 | 携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞 |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| MX2020013443A (es) | 2018-06-13 | 2021-02-26 | Novartis Ag | Receptores de antigeno quimerico de bcma y usos de los mismos. |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| AU2019290230A1 (en) * | 2018-06-22 | 2020-12-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 and CD19 |
| WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
| CN108913709A (zh) * | 2018-06-26 | 2018-11-30 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术（广州）有限公司 | Shp-1敲除的t细胞及其构建方法 |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| CA3105101A1 (en) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| WO2020000465A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种制备lightr基因敲除小鼠的方法 |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP3818146A4 (en) * | 2018-07-04 | 2022-10-19 | Cytoimmune Therapeutics, Inc. | COMPOSITIONS AND METHODS OF IMMUNOTHERAPY TARGETING FLT3, PD-1 AND/OR PD-L1 |
| CN112955548B (zh) * | 2018-07-09 | 2023-11-24 | 普众发现医药科技(上海)有限公司 | 叶酸受体α特异性抗体 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11952419B2 (en) * | 2018-07-10 | 2024-04-09 | University Of Connecticut | Reagents and methods for treating cancer and autoimmune disease |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| US12358999B2 (en) | 2018-07-27 | 2025-07-15 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| SG11202100947SA (en) | 2018-07-31 | 2021-03-30 | Daiichi Sankyo Co Ltd | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| KR20210042125A (ko) * | 2018-08-07 | 2021-04-16 | 퍼듀 리서치 파운데이션 | Car t 세포의 회생 |
| EP3833742A2 (en) | 2018-08-09 | 2021-06-16 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| KR20210046006A (ko) * | 2018-08-10 | 2021-04-27 | 상가모 테라퓨틱스 프랑스 | Tnfr2 도메인을 포함하는 신규한 car 작제물 |
| CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| AU2019331496A1 (en) | 2018-08-31 | 2021-03-18 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20200080056A1 (en) * | 2018-09-06 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL297931B2 (en) | 2018-09-25 | 2025-03-01 | Harpoon Therapeutics Inc | DLL3 binding proteins and methods of use |
| CN109265561B (zh) * | 2018-09-25 | 2021-05-25 | 山东兴瑞生物科技有限公司 | 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用 |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7596263B2 (ja) * | 2018-10-10 | 2024-12-09 | ザイムワークス ビーシー インコーポレイテッド | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| EP3640329A1 (en) * | 2018-10-18 | 2020-04-22 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Gene editing based cancer treatment |
| CN112912400B (zh) * | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| CN113454115B (zh) * | 2018-10-19 | 2025-06-13 | 纪念斯隆-凯特琳癌症中心 | 靶向唾液酸化路易斯a的嵌合抗原受体及其用途 |
| EP3870146A4 (en) * | 2018-10-25 | 2022-08-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy |
| WO2020092467A1 (en) | 2018-10-30 | 2020-05-07 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CN113286815B (zh) * | 2018-11-09 | 2024-04-26 | 弗雷德哈钦森癌症中心 | 间皮素特异性t细胞受体及其在免疫治疗中的应用 |
| CN111197032A (zh) * | 2018-11-16 | 2020-05-26 | 上海斯丹赛生物技术有限公司 | 嵌合抗原受体细胞分泌治疗剂 |
| CN113330034A (zh) | 2018-11-16 | 2021-08-31 | 阿尔伯特爱因斯坦医学院 | 针对B7-H3的IgV结构域的单克隆抗体及其用途 |
| WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US10918667B2 (en) * | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| EP3887978A4 (en) | 2018-11-29 | 2022-08-17 | Vineti Inc. | CENTRALIZED AND DECENTRALIZED CUSTOMIZED MEDICATION PLATFORM |
| MX2021006968A (es) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Antígeno quimérico y receptores de las células t, y métodos de uso. |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US20220016171A1 (en) * | 2018-12-18 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| WO2020132557A1 (en) | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| WO2020142672A2 (en) * | 2019-01-04 | 2020-07-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| PH12021551676A1 (en) * | 2019-01-18 | 2022-03-07 | Janssen Biotech Inc | Gprc5d chimeric antigen receptors and cells expressing the same |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US11321652B1 (en) | 2019-02-20 | 2022-05-03 | Vineti Inc. | Smart label devices, systems, and methods |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| EP4538380A3 (en) | 2019-02-22 | 2025-07-02 | Garvan Institute of Medical Research | Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP2022529280A (ja) | 2019-04-17 | 2022-06-20 | チャ バイオテック カンパニー リミテッド | 抗癌活性が増大されたナチュラルキラー細胞、及びその免疫治療用途 |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| CN114269777A (zh) * | 2019-04-26 | 2022-04-01 | 北卡罗来纳大学教堂山分校 | 嵌合抗原受体构建体及其在car-t细胞中的用途 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| AU2020266841A1 (en) * | 2019-04-30 | 2021-11-25 | Memorial Sloan-Kettering Cancer Center | Combination therapies |
| BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
| BR112021021075A2 (pt) | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| KR20250095757A (ko) | 2019-06-21 | 2025-06-26 | 카이트 파마 인코포레이티드 | TGF-β 수용체 및 이의 사용 방법 |
| WO2021009701A1 (en) * | 2019-07-17 | 2021-01-21 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
| AU2020319094A1 (en) * | 2019-07-24 | 2022-02-03 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof |
| US20220296727A1 (en) * | 2019-07-30 | 2022-09-22 | Dendrocyte Biotech Pty Ltd | Immunoconjugate |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| EP4013431A4 (en) | 2019-08-18 | 2024-05-01 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| CN110627909B (zh) * | 2019-08-28 | 2021-03-30 | 中国人民解放军第二军医大学 | 一种特异性活化nk细胞的嵌合抗原受体及其应用 |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| AU2020345943A1 (en) | 2019-09-10 | 2022-03-31 | Obsidian Therapeutics, Inc. | CA2-IL15 fusion proteins for tunable regulation |
| CN114729059A (zh) * | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| WO2021054789A1 (ko) * | 2019-09-18 | 2021-03-25 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| JP7690468B2 (ja) * | 2019-10-22 | 2025-06-10 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ |
| WO2021081232A1 (en) * | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | Modified cytotoxic t cells and methods of use thereof |
| WO2021081239A1 (en) * | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | T-cell modulatory chimeric molecules and methods of use thereof |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| CN110627903B (zh) * | 2019-10-29 | 2021-09-21 | 河南大学 | 抗cd97单克隆抗体、其可变区与恒定区序列及应用 |
| WO2021092007A1 (en) * | 2019-11-04 | 2021-05-14 | Verastem, Inc. | Methods of making cellular therapies |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| CA3159889A1 (en) * | 2019-11-28 | 2021-06-03 | CentricsBio, Inc. | Chimeric antigen receptor specifically binding to cd 300c antigen |
| EP4073111A1 (en) * | 2019-12-11 | 2022-10-19 | Cilag GmbH International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| WO2021127428A1 (en) * | 2019-12-18 | 2021-06-24 | Albert Einstein College Of Medicine | Chimeric antigen receptors targeting b7-h3 (cd276) and associated methods |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4087861A1 (en) * | 2020-01-08 | 2022-11-16 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| CN115427084A (zh) * | 2020-01-10 | 2022-12-02 | T细胞受体治疗公司 | 用于自身免疫调节的组合物和方法 |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| US20230111593A1 (en) | 2020-02-14 | 2023-04-13 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| MX2022010604A (es) | 2020-02-27 | 2022-09-09 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| EP4110377A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| CA3181566A1 (en) * | 2020-04-30 | 2021-11-04 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
| IL297916A (en) * | 2020-05-05 | 2023-01-01 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| AU2021286676B2 (en) * | 2020-06-11 | 2025-02-13 | Bioheng Therapeutics Limited | Engineered immune cell expressing NK inhibitory molecule and use thereof |
| US20230416359A1 (en) * | 2020-06-17 | 2023-12-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer |
| EP4170020A4 (en) * | 2020-06-17 | 2025-01-22 | Kyoto University | IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION |
| US20230235074A1 (en) * | 2020-06-19 | 2023-07-27 | Board Of Regents, The University Of Texas System | Anti-bst2 antibodies targeting bst2 long isoform |
| CN116813777A (zh) | 2020-06-22 | 2023-09-29 | 恩格姆生物制药公司 | Lair-1结合剂及其使用方法 |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 |
| CN116490518A (zh) | 2020-07-17 | 2023-07-25 | 西穆尔克斯股份有限公司 | 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法 |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| US12448457B2 (en) | 2020-08-05 | 2025-10-21 | Synthekine, Inc. | GP130 binding molecules and methods of use |
| KR20230061394A (ko) | 2020-08-05 | 2023-05-08 | 신테카인, 인크. | IL10Ra 결합 분자 및 사용 방법 |
| CN116829585A (zh) | 2020-08-05 | 2023-09-29 | 辛德凯因股份有限公司 | Il27受体结合相关的组合物和方法 |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| EP4192489A4 (en) | 2020-08-05 | 2024-12-11 | Synthekine, Inc. | IL2RB-BINDING MOLECULES AND METHODS OF USE |
| EP4192863A4 (en) * | 2020-08-05 | 2025-07-30 | Synthekine Inc | IL2RG BINDING MOLECULES AND METHODS OF USE |
| EP4192880A4 (en) | 2020-08-05 | 2025-04-30 | Synthekine, Inc. | IL10 receptor-binding molecules and methods of use |
| WO2022031870A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL27Rα BINDING MOLECULES AND METHODS OF USE |
| IL299911A (en) | 2020-08-14 | 2023-03-01 | Kite Pharma Inc | Improving immune cell function |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| US20240307539A1 (en) * | 2020-09-30 | 2024-09-19 | Institute Of Zoology, Chinese Academy Of Science | Egfr-targeting chimeric antigen receptor |
| CN114369168B (zh) * | 2020-10-19 | 2024-08-30 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| IL302700A (en) | 2020-11-13 | 2023-07-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| US20240002526A1 (en) * | 2020-11-17 | 2024-01-04 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| JP7688434B2 (ja) * | 2020-11-20 | 2025-06-04 | ブリス バイオファーマシューティカル（ハンゾウ）カンパニー，リミテッド | 親和性が低下した改変ｅｇｆｒ抗体、薬物複合体及びその使用 |
| MX2023006395A (es) | 2020-12-03 | 2023-06-15 | Century Therapeutics Inc | Celulas dise?adas geneticamente y usos de estas. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| CN113234169B (zh) | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US20240216427A1 (en) * | 2020-12-30 | 2024-07-04 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1) |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| JP2024504728A (ja) | 2021-01-26 | 2024-02-01 | サイトケアズ （シャンハイ） インコーポレイテッド | キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞 |
| CA3206241A1 (en) * | 2021-01-29 | 2022-01-28 | Guoqing Cao | Antigen binding protein and use thereof |
| JP2024505955A (ja) * | 2021-02-03 | 2024-02-08 | バイオヘン セラピューティクス リミテッド | 新型キメラ抗原受容体及びその使用 |
| CN112851826B (zh) * | 2021-02-10 | 2023-08-11 | 上海煦顼技术有限公司 | Upk2嵌合抗原受体及其尿道癌的治疗 |
| KR102671410B1 (ko) * | 2021-03-03 | 2024-06-04 | 진화섭 | RANK 리간드(RANK ligand)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| EP4305053A1 (en) | 2021-03-11 | 2024-01-17 | Kite Pharma, Inc. | Improving immune cell function |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| CN115386010A (zh) * | 2021-05-23 | 2022-11-25 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| EP4141028A1 (en) | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
| US11615874B1 (en) | 2021-09-30 | 2023-03-28 | Vineti Inc. | Personalized medicine and therapies platform |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| CN114015674B (zh) | 2021-11-02 | 2024-08-30 | 辉大(上海)生物科技有限公司 | 一种CRISPR-Cas12i系统 |
| EP4493581A1 (en) * | 2022-03-18 | 2025-01-22 | University of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| JPWO2024014470A1 (enExample) * | 2022-07-13 | 2024-01-18 | ||
| WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
| IL319225A (en) | 2022-09-15 | 2025-04-01 | Novartis Ag | Treatment of autoimmune disorders using antigen receptor chemotherapeutics |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| CN120225666A (zh) | 2022-11-21 | 2025-06-27 | 艾欧凡斯生物治疗公司 | 用于评估基因编辑的t细胞的增殖效力的方法 |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| WO2024186656A1 (en) | 2023-03-03 | 2024-09-12 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| WO2024215989A1 (en) * | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2024215987A1 (en) * | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2025007073A2 (en) | 2023-06-29 | 2025-01-02 | Dispatch Biotherapeutics, Inc. | Synthetic cytokine receptors |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| EP4520346A1 (en) | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026008700A1 (en) | 2024-07-03 | 2026-01-08 | Immunofusion Bv | Il7r alpha signalling domain, chimeric antigen receptor and uses thereof |
Family Cites Families (295)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US504048A (en) | 1893-08-29 | Sulky | ||
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| CZ287296B6 (en) | 1992-01-23 | 2000-10-11 | Merck Patent Gmbh | Antibody construct and structural kit for selective preparation thereof |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| EP0640130B1 (en) | 1992-05-08 | 1998-04-15 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5843674A (en) | 1993-11-16 | 1998-12-01 | Pola Chemical Industries Inc. | Anti-human tyrosinase monoclonal antibody |
| CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| EP0756604A1 (en) | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6294353B1 (en) | 1994-10-20 | 2001-09-25 | Morphosys Ag | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| JP3066983B2 (ja) | 1995-01-18 | 2000-07-17 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| ATE274064T1 (de) | 1995-05-23 | 2004-09-15 | Morphosys Ag | Multimere proteine |
| KR100400620B1 (ko) | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | 라파마이신유도체 |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6239259B1 (en) | 1996-04-04 | 2001-05-29 | Unilever Patent Holdings B.V. | Multivalent and multispecific antigen-binding protein |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP0920505B1 (en) | 1996-08-16 | 2008-06-04 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| AU5158098A (en) | 1996-10-25 | 1998-05-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions for inhibiting inflammation and angiogenesis compri sing a mammalian CD97 alpha subunit |
| EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| AU736707B2 (en) | 1997-06-11 | 2001-08-02 | Anaphore, Inc. | Trimerising module |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
| CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE69925909T2 (de) | 1998-04-15 | 2006-05-11 | Brigham & Women's Hospital, Inc., Boston | T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| EP1100830B1 (en) | 1998-07-28 | 2003-10-01 | Micromet AG | Heterominibodies |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| HU230583B1 (hu) | 1999-08-17 | 2017-02-28 | Biogen Idec Ma Inc. | BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként |
| WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| WO2001023432A1 (en) | 1999-09-30 | 2001-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| CA2409991A1 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| ATE545703T1 (de) | 2000-07-25 | 2012-03-15 | Immunomedics Inc | Multivalentes zielbindendes protein |
| US20040242847A1 (en) | 2000-10-20 | 2004-12-02 | Naoshi Fukushima | Degraded agonist antibody |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP2281837B1 (en) | 2001-08-10 | 2016-10-05 | Aberdeen University | Antigen binding domains from fish |
| EP2383290B1 (en) | 2001-08-23 | 2019-05-08 | Rsr Limited | Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| EP1470159B1 (en) | 2001-12-04 | 2013-08-07 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
| US20030211078A1 (en) | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| CA2472341C (en) | 2002-02-01 | 2011-06-21 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
| KR20040088572A (ko) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
| GB0208104D0 (en) | 2002-04-09 | 2002-05-22 | Univ Dundee | Method |
| ATE512989T1 (de) | 2002-04-15 | 2011-07-15 | Chugai Pharmaceutical Co Ltd | Verfahren zur herstellung von scdb-bibliotheken |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| DE50306067D1 (de) | 2002-11-26 | 2007-02-01 | Brahms Ag | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| AU2004232928A1 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| AU2004289172A1 (en) | 2003-06-27 | 2005-05-26 | Diadexus, Inc. | Pro 104 antibody compositions and methods of use |
| AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| EP1660534A2 (en) | 2003-08-22 | 2006-05-31 | MedImmune, Inc. | Humanization of antibodies |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035577A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | ガングリオシドｇｄ３に特異的に結合する抗体組成物 |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| EP1697748A4 (en) | 2003-12-22 | 2007-07-04 | Centocor Inc | METHODS FOR GENERATING MULTIMEDIA MOLECULES |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| WO2006107617A2 (en) | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| AU2006262711B2 (en) | 2005-05-17 | 2013-01-31 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| KR20080019249A (ko) | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| HRP20080053A2 (hr) | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| ATE452913T1 (de) | 2005-08-26 | 2010-01-15 | Pls Design Gmbh | Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen |
| JP5270353B2 (ja) | 2005-10-07 | 2013-08-21 | エクセリクシス， インク． | ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法 |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| NZ568551A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to Fucosyl-GM1 and methods using anti-Fucosyl-GM1 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| CA2636111C (en) | 2006-01-13 | 2018-04-03 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
| JP2009526857A (ja) | 2006-02-15 | 2009-07-23 | イムクローン・リミテッド・ライアビリティ・カンパニー | 機能性抗体 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007112362A2 (en) | 2006-03-24 | 2007-10-04 | The Regents Of The University Of California | Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition |
| WO2007110648A1 (en) | 2006-03-29 | 2007-10-04 | King's College London | Agonist antibodies against tshr |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| ES2469676T3 (es) | 2006-05-25 | 2014-06-18 | Bayer Intellectual Property Gmbh | Complejos moleculares dim�ricos |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| NZ596865A (en) | 2006-06-12 | 2013-07-26 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
| AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| JP2010505775A (ja) | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体 |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| WO2008140477A2 (en) | 2006-11-02 | 2008-11-20 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
| WO2008101234A2 (en) | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| US7635753B2 (en) | 2007-02-19 | 2009-12-22 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| EP2514766A3 (en) | 2007-03-29 | 2013-06-05 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| CN101802015B (zh) | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| CA2691785C (en) | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| US8344112B2 (en) | 2007-07-31 | 2013-01-01 | Merck Sharp & Dohme Limited | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US9624309B2 (en) | 2007-08-15 | 2017-04-18 | Bayer Intellectual Property Gmbh | Monospecific and multispecific antibodies and method of use |
| WO2009052623A1 (en) | 2007-10-26 | 2009-04-30 | Governing Council Of The University Of Toronto | Therapeutic and diagnostic methods using tim-3 |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| WO2009068649A2 (en) | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| RU2010138647A (ru) | 2008-02-21 | 2012-03-27 | Астразенека Аб (Se) | Комбинированная терапия 238 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| JP5798919B2 (ja) | 2008-08-25 | 2015-10-21 | アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． | Ｐｄ−１アンタゴニストの組成物および使用方法 |
| EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
| US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
| WO2010033866A2 (en) | 2008-09-19 | 2010-03-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| DK2414362T3 (da) | 2009-04-03 | 2014-09-22 | Verastem Inc | Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| AU2010243211B2 (en) | 2009-04-30 | 2014-01-30 | Ramot At Tel Aviv University Ltd. | Anti CEACAM1 antibodies and methods of using same |
| US8871191B2 (en) | 2009-08-14 | 2014-10-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of IL-15 preparations to treat lymphopenia |
| PL3023438T3 (pl) | 2009-09-03 | 2020-07-27 | Merck Sharp & Dohme Corp. | Przeciwciała anty-gitr |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US8772459B2 (en) | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| EP2516468B1 (en) | 2009-12-23 | 2016-03-02 | Synimmune GmbH | Anti-flt3 antibodies and methods of using the same |
| AU2010343056A1 (en) | 2009-12-29 | 2012-08-02 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| KR20240052894A (ko) | 2010-02-24 | 2024-04-23 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| CN103347894B (zh) | 2010-06-19 | 2017-05-10 | 纪念斯隆-凯特林癌症中心 | 抗gd2抗体 |
| EA201390085A1 (ru) | 2010-07-09 | 2013-06-28 | Экселиксис, Инк. | Композиции ингибиторов киназ для лечения рака |
| RU2013106427A (ru) | 2010-07-16 | 2014-08-27 | Пирамал Энтерпрайзис Лимитед | Замещенные имидазохинолиновые производные в качестве ингибиторов киназы |
| EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PE20141271A1 (es) | 2011-04-01 | 2014-10-08 | Sloan Kettering Inst Cancer | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| EA201790330A1 (ru) | 2011-05-27 | 2018-02-28 | Глаксо Груп Лимитед | Белки, связывающиеся с bcma (cd269/tnfrsf17) |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CN103957918A (zh) | 2011-08-11 | 2014-07-30 | 因特利凯有限责任公司 | 激酶抑制剂多晶型物 |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| WO2013040371A2 (en) | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
| ES2739808T3 (es) | 2011-10-27 | 2020-02-04 | Genmab As | Producción de proteínas heterodiméricas |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| ES2753614T3 (es) | 2011-12-01 | 2020-04-13 | Brigham & Womens Hospital Inc | Anticuerpos recombinantes anti-CEACAM1 para terapia contra el cáncer |
| US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
| KR20140126357A (ko) * | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| AR090903A1 (es) | 2012-05-01 | 2014-12-17 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17 |
| US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| EP3698809A1 (en) | 2012-07-31 | 2020-08-26 | The Brigham & Women's Hospital, Inc. | Modulation of the immune response using agents binding tim-3 and ceacam-1 |
| AR092745A1 (es) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| EP3679950A1 (en) | 2012-10-12 | 2020-07-15 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
| EP4234696A3 (en) | 2012-12-12 | 2023-09-06 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20160008399A1 (en) | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| KR20230100748A (ko) * | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| IL292924A (en) * | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| AU2023365081A1 (en) * | 2022-10-18 | 2025-05-01 | Kite Pharma, Inc. | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same |
| IL320155A (en) * | 2022-10-18 | 2025-06-01 | Kite Pharma Inc | Novel cd19 binders, car-t constructs comprising the same, and methods of using the same |
-
2015
- 2015-03-13 CN CN201580013987.3A patent/CN106163547A/zh active Pending
- 2015-03-13 ES ES15712503T patent/ES2939760T3/es active Active
- 2015-03-13 EP EP15712503.0A patent/EP3119423B1/en active Active
- 2015-03-13 WO PCT/US2015/020606 patent/WO2015142675A2/en not_active Ceased
- 2015-03-13 JP JP2016557287A patent/JP2017513818A/ja active Pending
- 2015-03-13 EP EP19169356.3A patent/EP3593812A3/en active Pending
- 2015-03-13 US US15/126,036 patent/US20170335281A1/en not_active Abandoned
-
2019
- 2019-07-05 JP JP2019126002A patent/JP6860623B2/ja active Active
- 2019-10-11 US US16/599,988 patent/US20200283729A1/en active Pending
-
2021
- 2021-03-26 JP JP2021053240A patent/JP7526121B2/ja active Active
-
2024
- 2024-07-19 JP JP2024115421A patent/JP2024164002A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513818A5 (enExample) | ||
| RU2019133286A (ru) | Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью | |
| JP2020513828A5 (enExample) | ||
| IL295878A (en) | Methods for producing cells expressing a chimeric antigen receptor | |
| JP2020500530A5 (enExample) | ||
| JP2018527008A5 (enExample) | ||
| US20190321404A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| CN112771167B (zh) | 表达有趋化因子的细胞及用途 | |
| JP2019500394A5 (enExample) | ||
| JP2019525956A5 (enExample) | ||
| EP3822345B1 (en) | Genetically engineered cell and application thereof | |
| CN110582509A (zh) | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 | |
| JP2019532953A5 (enExample) | ||
| JPWO2020047452A5 (enExample) | ||
| RU2018127657A (ru) | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью | |
| JP2019513347A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| EP3909590A1 (en) | Cellular immunotherapy combination | |
| EP3728322A1 (en) | Single- and multi-chain chimeric antigen receptors | |
| JPWO2021173985A5 (enExample) | ||
| JPWO2021252920A5 (enExample) | ||
| KR20240153592A (ko) | 동종이계 치료용 세포 | |
| JPWO2022242700A5 (enExample) |